N V Rajeshkumar
Overview
Explore the profile of N V Rajeshkumar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
3108
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fan W, Liu H, Stachelek G, Begum A, Davis C, Dorado T, et al.
bioRxiv
. 2024 Aug;
PMID: 39211199
Ribosome biosynthesis is a cancer vulnerability executed by targeting RNA polymerase I (Pol I) transcription. We developed advanced, specific Pol I inhibitors to identify drivers of this sensitivity. By integrating...
2.
Dorado T, de Leon P, Begum A, Liu H, Chen D, Rajeshkumar N, et al.
ACS Med Chem Lett
. 2022 Apr;
13(4):608-614.
PMID: 35450366
RNA polymerase I (Pol I) transcribes ribosomal DNA (rDNA) into the 47S ribosomal RNA (rRNA) precursor. Further processing produces the 28S, 5.8S, and 18S rRNAs that are assembled into mature...
3.
Fan W, Eklund E, Sherman R, Liu H, Pitts S, Ford B, et al.
RNA
. 2022 Feb;
28(4):478-492.
PMID: 35110373
Polymorphism drives survival under stress and provides adaptability. Genetic polymorphism of ribosomal RNA (rRNA) genes derives from internal repeat variation of this multicopy gene, and from interindividual variation. A considerable...
4.
De Jesus-Acosta A, Sugar E, ODwyer P, Ramanathan R, Von Hoff D, Rasheed Z, et al.
Br J Cancer
. 2019 Dec;
122(4):498-505.
PMID: 31857726
Background: The Hedgehog (Hh) signalling pathway is overexpressed in pancreatic ductal adenocarcinoma (PDA). Preclinical studies have shown that Hh inhibitors reduce pancreatic cancer stem cells (pCSC), stroma and Hh signalling....
5.
Rajeshkumar N, Kers J, Moncrief S, Defusco A, Park J, Handfield M
Toxicol Appl Pharmacol
. 2019 Apr;
374:32-40.
PMID: 31034929
Clostridium difficile associated disease (CDAD) is the leading infectious cause of antibiotic-associated diarrhea and colitis in the United States. Both the incidence and severity of CDAD have been increased over...
6.
Begum A, McMillan R, Chang Y, Penchev V, Rajeshkumar N, Maitra A, et al.
Pancreas
. 2019 Feb;
48(3):329-334.
PMID: 30747824
Objective: Cancer-associated fibroblasts (CAFs) play an important role in the progression of pancreatic ductal adenocarcinoma (PDAC) by promoting tumor cell migration and drug resistance. We determined the impact of CAFs...
7.
Ramanathan R, Weiss G, Posner R, Rajeshkumar N, Jameson G, Aziz M, et al.
J Gastrointest Oncol
. 2018 Jan;
8(6):925-935.
PMID: 29299351
Background: The choice of a regimen in metastatic pancreatic cancer patients following progression on 1st line therapy is empiric and outcomes are unsatisfactory. This phase II study was performed to...
8.
Ludwig K, Du W, Sorrelle N, Wnuk-Lipinska K, Topalovski M, Toombs J, et al.
Cancer Res
. 2017 Nov;
78(1):246-255.
PMID: 29180468
Activation of the receptor tyrosine kinase Axl is associated with poor outcomes in pancreatic cancer (PDAC), where it coordinately mediates immune evasion and drug resistance. Here, we demonstrate that the...
9.
Begum A, Ewachiw T, Jung C, Huang A, Norberg K, Marchionni L, et al.
PLoS One
. 2017 Jul;
12(7):e0180181.
PMID: 28692661
Cancer stem cells (CSCs) play an important role in the clonogenic growth and metastasis of pancreatic ductal adenocarcinoma (PDAC). A hallmark of PDAC is the desmoplastic reaction, but the impact...
10.
Rajeshkumar N, Yabuuchi S, Pai S, de Oliveira E, Kamphorst J, Rabinowitz J, et al.
Clin Cancer Res
. 2017 Jun;
23(18):5639-5647.
PMID: 28611197
To identify effective metabolic inhibitors to suppress the aggressive growth of pancreatic ductal adenocarcinoma (PDAC), we explored the antitumor efficacy of metabolic inhibitors, as single agents, in a panel of...